Compare AstraZeneca plc (AZN) vs Walmart Stores Inc (WMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Walmart Stores Inc — how do they compare? AstraZeneca plc trades at $166.66 (market cap $253.13B), while Walmart Stores Inc trades at $113.73 (market cap $904.83B). The key difference: Walmart Stores Inc is far larger — about 3.6× AstraZeneca plc's market cap, and AstraZeneca plc pays the higher dividend (1.92%). Which is the better fit depends on your goals.
| AZN | WMT | |
|---|---|---|
Market Cap | $253.13B | $904.83B |
Sector | Health | Consumer Staples |
52-Week High | $209.48 | $134.20 |
52-Week Low | $137.44 | $95.05 |
Enterprise Value | $279.37B | $968.28B |
Dividend Yield | 1.92% | 0.87% |
Volume | — | 5,675,288 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Walmart (WMT) trades at $113.7, down 0.18% on the day, with a bearish technical signal and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.66 meeting expectations. Revenue grew to $681.0 billion in 2025, with net income reaching $19.44 billion. Analyst consensus is strongly bullish, with a $142.10 price target and 72.72% buy ratings. Recent news highlights operational updates, including drone delivery expansion and AI tool development.
The outlook for WMT is positive, driven by consistent earnings performance and strategic initiatives in e-commerce and technology. Risks include competitive pressures from Amazon, which recently surpassed Walmart in revenue, and potential legal issues from product liability suits. The stock offers a solid dividend and growth potential, but investors should monitor margin pressures and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
